28 kDa GST proteins from schistosoma for the use thereof in the treatment of inflammatory autoimmune diseases generating a Th1 and/or Th17 response
US9593313B2 · kind B2 · utility
8Cited by
0References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 6, 2013 |
| Grant date | Mar 14, 2017 |
| Priority date | — |
| Expiry date | Feb 6, 2033 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kDa glutathione S-transferase protein from a schistosome selected from Schistosoma haematobium, Schistosoma mansoni, Schistosoma bovis represented respectively by the sequences SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 for the use thereof in the treatment of an inflammatory autoimmune disease generating a response of type Th1 and/or Th17.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.